Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears ...

HealthDay News — Two widely consumed food additive mixtures may increase type 2 diabetes incidence, according to a study published online April 8 in PLOS Medicine.

Proposal includes steps that need to be taken to strengthen preparedness, readiness, and health system functions and resilience.

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

HealthDay News — Cannabidiol (CBD) cannabis extracts appear to provide meaningful benefits for children and adolescents with autism spectrum disorder (ASD), according to a review presented at the ...

Treatment options are limited for those with sudden liver failure and the condition has a death rate as high as 50%.

SNAP, which helped nearly 42 million Americans in 2024 and cost about $100 billion, is overseen by the US Department of Agriculture but run by individual states.

Prevalence was 3.4 times higher among boys than girls and was lower among White children versus those of other races/ethnicities ...